Deucravacitinib (BMS-986165)

Independent reference data for Deucravacitinib (BMS-986165) (CAS 1609392-27-9), compiled from public chemistry databases.

Registry identifiers across databases

Computed descriptors

Documented uses on record

Deucravacitinib is a tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It is not recommended for use in combination with other potent immunosuppressants. It is also indicated for the treatment of psoriatic arthritis in adults.Deucravacitinib is a small molecule inhibitor of tyrosine kinase 2 that is used in the treatment of moderate-to-severe plaque psoriasis. Deucravacitinib is associated with transient and usually mild elevations in serum aminotransferase levels during therapy but has not been linked instances of clinically apparent acute liver injury.

Synonyms and trade names

Deucravacitinib; 1609392-27-9; BMS-986165; Sotyktu; N0A21N6RAU; RefChem:58358; Tyk2-IN-4; BMS986165; Deucravacitinib [USAN]; MFCD31715455; Deucravacitinib (BMS-986165); Tyk2-IN-4(BMS986165); bms 986165; Sotyktu (TN); Deucravacitinib [MI]; UNII-N0A21N6RAU

Regulatory listings held on file

GHS notification summary	33.3% (1 / 3)

GHS hazard classification

GHS notification summary	33.3% (1 / 3)
Reported hazard statements	H361 (33.3%), H372 (66.7%)

This chemical does not meet GHS hazard criteria for 33.3% (1 of 3) of reports.

H361 (33.3%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]

What the public record says

Deucravacitinib (BMS-986165) · CAS 1609392-27-9 · C20H22N8O3. UNII N0A21N6RAU.

Source: PubChem / Wikidata; the batch COA governs where values differ.